Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00045331 · ClinicalTrials.gov registry record · NA

Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer

A NA study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
NA
Development phase

NCT00045331: Completed NA study, sponsored by National Cancer Institute (NCI).

NCT00045331 is a NA study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00045331, a NA study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
NA
Development phase

Study Summary

RATIONALE: Proteins found in blood and urine samples may help predict outcome and allow doctors to plan more effective treatment. PURPOSE: Diagnostic trial to study blood and urine proteins in predicting treatment outcome in patients who are undergoing radiation therapy for prostate cancer.

Interventions

  • GENETIC proteomic profiling

Trial Details

FieldValue
Start Date 2002-08
Est. Completion 2007-10
Phase NA
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00045331 record still lists

NCT00045331 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which proteomic profiling is the first listed.

NCT00045331 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00045331 about?

NCT00045331 is a clinical study titled "Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer". RATIONALE: Proteins found in blood and urine samples may help predict outcome and allow doctors to plan more effective treatment. PURPOSE: Diagnostic trial to study blood and urine proteins in predicting treatment outcome in patients who are undergoing radiation therapy for prostate cancer.

What is the current status of trial NCT00045331?

This trial is currently completed. It is a NA study. The study started on 2002-08. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00045331?

The interventions under investigation include: proteomic profiling (GENETIC).

Who is sponsoring clinical trial NCT00045331?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00045331, the US trial registry maintained by the National Library of Medicine. NCT00045331 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.